人肺癌裸小鼠模型活体成像的动态观察  

Dynamic observation of in vivo biofluorescence imaging in nude mouse model with human lung carcinoma

作　　者：闫明霞[1] 刘蕾[1] 荚德水[1] 朱淼鑫[1] 吴海燕[1] 孔韩卫[1] 姚明[1] 

机构地区：[1]上海市肿瘤研究所实验病理研究室,上海200032

出　　处：《肿瘤》2008年第10期833-836,共4页Tumor

基　　金：上海市科学技术委员会计划项目(编号:071409009;064909001)

摘　　要：目的：建立稳定表达绿色荧光蛋白的人肺癌细胞系，并探讨小动物活体荧光成像系统在肺癌皮下移植瘤模型中的应用。方法：用慢病毒转染的方法建立表达绿色荧光蛋白的人肺癌细胞系NCI-H460．GFP，接种至裸小鼠体内建立皮下移植瘤模型，通过小动物活体成像系统连续5周观察肿瘤在小鼠皮下的动态生长情况。结果：建立了转染率接近100％的人肺癌NCI-H460-GFP细胞系，在体外及裸小鼠体内均能够长期稳定表达绿色荧光蛋白。活体荧光成像观察发现，1～4周随着肿瘤体积逐渐增大，平均荧光光子数逐渐增加；5周时随着肿瘤出现明显坏死，平均荧光光子数呈现下降趋势。结论：稳定表达绿色荧光蛋白的NCI—H460-GFP细胞系及其动物模型可以为肺癌研究提供理想的实验材料，应用小动物活体成像系统能够客观定量评价肿瘤在动物体内的生长情况。Objective ： To establish a human lung carcinoma cell line with stable expression of green fluorescent protein, and discuss the application of in vivo biofluorescence imaging system in subcutaneously xenografted tumor model. Methods： Human lung carcinoma NCI-H460-GFP cell line was established by tranfection of NCI-H460 ceils with green fluorescent protein （GFP） gene via lentiviral vector. The NCI-H460-GFP cells were inoculated into the nude mice to prepare the subcutaneously xenografted tumor model. The dynamic growth of xenografted tumor was observed using in vivo fluorescence imaging system for subsequent 5 weeks. Results ： We successfully built up a human lung carcinoma NCI-H460-GFP cell line with transfection rate of nearly 100% , which can stably express high level of GFP protein in vitro and in vivo. In vivo fluorescence imaging found that the mean fluorescent intensity gradually increased with the increase in tumor volume in nude mice from one week to four weeks, however, the mean fluorescent intensity tended to decline when the tumor had apparent necrosis at the fifth week. Conclusion ： NCI-H460-GFP cell line with stable expression of GFP and its animal model provide useful experimental materials for lung cancer study. The in vivo fluorescence imaging system could be used to quantitatively eva-luate the tumor gowth in vivo.

关 键 词：肺肿瘤 绿色荧光蛋白质类 小鼠 裸 

分 类 号：R734.2[医药卫生—肿瘤] R73-354[医药卫生—临床医学]